Literature DB >> 9503219

Volume therapy in the critically ill: is there a difference?

J Boldt1, M Müller, D Mentges, M Papsdorf, G Hempelmann.   

Abstract

OBJECTIVE: There are still several concerns about the extensive and prolonged use of hydroxyethylstarch solution (HES) in critically ill patients. The effects of volume replacement with HES over 5 days on hemodynamics, laboratory data, and organ function were compared with volume therapy using human albumin (HA).
DESIGN: Prospective, randomized study.
SETTING: Clinical investigations on a surgical intensive care unit (ICU) of a university hospital. PATIENTS: 150 traumatized patients (injury severity score > 15) and 150 postoperative patients with sepsis were analyzed.
INTERVENTIONS: Either 10% low-molecular weight HES (HES-trauma, n = 75; HES-sepsis, n = 75) or 20% HA (HA-trauma, n = 75; HA-sepsis, n = 75) was given for 5 days to maintain the pulmonary capillary wedge pressure (PCWP) between 12 and 15 torr. The entire management of therapy of the patients was performed by physicians who were not involved in the study and blinded to the infusion regimen. MEASUREMENTS AND
RESULTS: In addition to extensive cardiorespiratory monitoring, several routine laboratory parameters for assessing pulmonary, renal, hepatic, and coagulation function were analyzed from arterial blood samples on the day of admission to the ICU and on the day of sepsis diagnosis, respectively ("baseline" value) and daily over the following 5 days. Mortality during and after the study did not differ significantly between the infusion groups. There were also no differences between the incidence of pulmonary, renal, or hepatic failure in the two subgroups. Mean arterial pressure, heart rate, and PCWP were similar in both subgroups, whereas cardiac index, oxygen delivery index, oxygen consumption index, and the ratio between the partial pressure of oxygen in arterial blood and fractional inspired oxygen were higher in the HES- than in the HA-treated groups. Standard coagulation parameters did not differ, albumin concentration increased significantly in both HA groups, and lactate concentrations decreased only in the HES-sepsis patients (from 2.8 +/- 0.5 to 1.5 +/- 0.4 mg/dl). Volume replacement using albumin was significantly (p < 0.001) more costly than therapy with HES.
CONCLUSIONS: Volume therapy with 10% HES for 5 days in the ICU patient showed no disadvantages compared with an infusion regimen using 20% albumin. Volume replacement using HES may even be associated with improved hemodynamics. HES appears to be a valuable and significantly cheaper alternative to albumin--even for prolonged volume therapy in the critically ill patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9503219     DOI: 10.1007/s001340050511

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  24 in total

1.  Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals.

Authors:  Rinaldo Bellomo; Shigehiko Uchino; Toshio Naka; Li Wan
Journal:  Intensive Care Med       Date:  2004-03-30       Impact factor: 17.440

2.  Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution.

Authors:  Christoph Eisenbach; Alexander H Schönfeld; Norbert Vogt; Moritz N Wente; Jens Encke; Wolfgang Stremmel; Eike Martin; Ernst Pfenninger; Markus A Weigand
Journal:  Intensive Care Med       Date:  2007-06-07       Impact factor: 17.440

3.  Research accomplishments that are too good to be true.

Authors:  John P A Ioannidis
Journal:  Intensive Care Med       Date:  2013-10-16       Impact factor: 17.440

Review 4.  Adjunctive drug treatment in severe hypoxic respiratory failure.

Authors:  S Elsasser; H Schächinger; W Strobel
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 5.  Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use?

Authors:  Christiane S Hartog; Frank M Brunkhorst; Christoph Engel; Andreas Meier-Hellmann; Maximilian Ragaller; Tobias Welte; Evelyn Kuhnt; Konrad Reinhart
Journal:  Wien Klin Wochenschr       Date:  2011-03-01       Impact factor: 1.704

Review 6.  Hydroxyethylstarch as a risk factor for acute renal failure: is a change of clinical practice indicated?

Authors:  Joachim Boldt
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Capillary leakage in post-cardiac arrest survivors during therapeutic hypothermia - a prospective, randomised study.

Authors:  Bård E Heradstveit; Anne Berit Guttormsen; Jørund Langørgen; Stig-Morten Hammersborg; Tore Wentzel-Larsen; Rune Fanebust; Elna-Marie Larsson; Jon-Kenneth Heltne
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-05-25       Impact factor: 2.953

8.  [Study protocol of the VISEP study. Response of the SepNet study group].

Authors:  K Reinhart; F M Brunkhorst; C Engel; F Bloos; A Meier-Hellmann; M Ragaller; N Weiler; O Moerer; M Gruendling; M Oppert; S Grond; D Olthoff; U Jaschinski; S John; R Rossaint; T Welte; M Schaefer; P Kern; E Kuhnt; M Kiehntopf; T Deufel; C Hartog; H Gerlach; F Stüber; H-D Volk; M Quintel; M Loeffler
Journal:  Anaesthesist       Date:  2008-07       Impact factor: 1.041

Review 9.  PRO: hydroxyethylstarch can be safely used in the intensive care patient--the renal debate.

Authors:  Joachim Boldt
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

10.  Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial.

Authors:  Thiemo F Veneman; Jeroen Oude Nijhuis; Arend J J Woittiez
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.